New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
13:20 EDTGWPHGW jumps ahead of CNN documentary on medical marijuana
Shares of GW Pharmaceuticals (GWPH) are climbing after research firm Piper Jaffray predicted that the stock could be boosted by a CNN documentary on medicinal marijuana expected to air tomorrow night. GW Pharmaceuticals is developing a number of drugs based on cannabinoids, one of the components of marijuana. WHAT'S NEW: After viewing a preview of the CNN documentary, Piper analyst Dr. Joshua Schimmer wrote that the show is likely to include statements from GW Pharmaceuticals and visits to the company. As a result, GW should become more closely associated with medical marijuana, and the stock could rise, Schimmer forecast. Moreover, the documentary will reinforce the effectiveness of using cannabinoids to treat epilepsy, according to the analyst, who noted that GW has created a cannabinoid based drug for the treatment of seizures. The documentary will emphasize the role of drugs derived from cannabinoids in treating other indications, including pain and multiple sclerosis spasticity, according to the analyst. GW is exploring using cannabinoids to treat both of those indications, and the documentary could remind investors that the company can expand beyond its epilepsy treatment, Schimmer contended. Moreover, the documentary could result in the FDA speeding up the approval process for GW's epilepsy drug, according to Schimmer, who reiterated a $97 price target and Overweight rating on GW. PRICE ACTION: In mid-afternoon trading, GW jumped $3.64, or 5%, to $76.05.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
07:58 EDTGWPHGW Pharmaceuticals re-initiated with a Buy at Roth Capital
Subscribe for More Information
November 20, 2015
06:01 EDTGWPHGW Pharmaceuticals selloff yesterday an overreaction, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says shares of GW Pharmaceuticals sold off yesterday in response to an abstract posted for the American Epilepsy Society conference in December describing a single center's experience with Epidiolex for seizures. The results support the drug's potent activity in Dravet syndrome, but some investors have concern with the drop-out rate due to inactivity and the lower response rate compared to what has otherwise been described for Epidiolex, Schimmer told investors last night in a research note titled "Over-Reacting To A Tree When The Forest Remains In Good Shape." The dropout rate is likely a result of the center's "highly questionable" practice of stopping drug if seizure reduction doesn't reach 50%, while the lower response rate at one site shouldn't detract from a "much bigger, robust clinical experience spanning multiple centers," Schimmer argues. He reiterates an Overweight rating on GW with a $147 price target. The stock closed yesterday down $5.42 to $82.30.
November 19, 2015
15:33 EDTGWPHGW Pharmaceuticals drops 10% after epilepsy study abstract posted
The conclusion of the abstract, posted to the the site of the American Epilepsy Society, stated: "Add-on pure CBD was associated with more than 50% seizure reduction in one-third of patients at 3 months...Best results were obtained in patients with Dravet syndrome, although one experienced a severe increase in seizure frequency."
15:31 EDTGWPHAbstract for GW Pharmaceuticals epilepsys study posted to AES site
Subscribe for More Information
November 16, 2015
07:16 EDTGWPHHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use